logo
Sign in

Corcept Therapeutics

Menlo Park, CA · Biotech · Public

Cortisol modulation therapies for treating serious diseases

Claim this profile

Follows are private to you and power your alerts

Updated · corcept.com

Sector
Biotech
Headquarters
Menlo Park, CA
Latest Form D
$525K, Apr 2012
Total capital
$26.3M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$26.2M
3 Form D · last Apr 2012
175 months since last filing
Federal contracts
$132K
13 awards · Veterans Affairs
Rank in Biotech#318 of 4373
Granted patents
18
22 pending · first 2025
Rank in peer group#14 of 1449

Capital timeline

20092011201320152017FEDERAL ↑EQUITY ↓Cumulative $26.3M$4K$4K$16K$73K$7K1st Form D$18M2nd Form D$7.7M3rd Form D$525K
20092011201320152017FEDERAL ↑EQUITY ↓Cumulative $26.3M$16K$73K$7K3rd Form D$525K

Latest events

  • Federal contractVeterans Affairs · Mifepristone$7K
  • Federal contractVeterans Affairs · Korlym Medication$73K
  • Federal contractVeterans Affairs · Korlym For Rlr Vamc Pharmacy$16K
  • Federal contractVeterans Affairs · Korylm Medication - 300MG, Tab, 28/BOTTLE, Qty 1 Bottle$4K
  • Federal contractVeterans Affairs · Korylm Medication, 300MG, Tablets, 28/BT - Qty. 1$4K
  • Federal contractVeterans Affairs · Mifepristone (korylm) 300MG$4K
  • Federal contractVeterans Affairs · Korylm - Medication$4K
  • Private capital raisedForm D · SEC · 3rd filing$525K
  • Private capital raisedForm D · SEC · 2nd filing$7.7M
  • Private capital raisedForm D · SEC · 1st filing$18M
Show 5 earlier federal awards
  • Federal contractVeterans Affairs · Mifepristone Krylm Tablet$4K
  • Federal contractVeterans Affairs · 1 Mifepristone (korylm) 300MG Tablet$4K
  • Federal contractVeterans Affairs · Korylm Tablets - Emergency$4K
  • Federal contractVeterans Affairs · Mifepristone (korylm) Tablets$4K
  • Federal contractVeterans Affairs · Igf::ot::igf - Mifepristone 300MG Tablet, 28CT$4K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

1 record has no date or no amount, so it isn’t placed on the timeline.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#14 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Anne M. LeDouxExecutive OfficerNamed in SEC Form D filings
  • Caroline M. LoewyExecutive OfficerNamed in SEC Form D filings
  • Charles L. RobbExecutive OfficerNamed in SEC Form D filings
  • David L. MahoneyDirectorNamed in SEC Form D filings
  • Edward E. PenhoetDirectorNamed in SEC Form D filings
  • G. Leonard Baker, Jr.DirectorNamed in SEC Form D filings
Show all 14 people
  • James A. HarperDirectorNamed in SEC Form D filings
  • James N. WilsonDirectorNamed in SEC Form D filings
  • Joseph K. Belanoff, M.D.Executive Officer, DirectorNamed in SEC Form D filings
  • Joseph C. Cook, Jr.DirectorNamed in SEC Form D filings
  • Joseph L. TurnerDirectorNamed in SEC Form D filings
  • Patrick G. EnrightDirectorNamed in SEC Form D filings
  • Robert L. Roe, M.D.Executive OfficerNamed in SEC Form D filings
  • Steven M. LoExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 18 granted of 40
  • GrantedPyrylium Method Of Preparing Pyrimidine Cyclohexyl Glucocorticoid Receptor ModulatorsUSPTOUS 12,735,390
  • PendingConcomitant Administration Of Glucocorticoid Receptor Modulator Relacorilant And Paclitaxel, A Dual Substrate Of CYP2C8 And CYP3A4USPTOApplication 19552476
  • PendingConcomitant Administration Of Glucocorticoid Receptor Modulator Relacorilant And CYP2C8 SubstratesUSPTOApplication 19655579
Show all 40 patent records

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .